ファーマ4.0の市場規模、シェア、動向分析レポート：タイプ別、技術別、最終用途別、地域別、セグメント別予測、2024年～2030年

ファーマ4.0市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のファーマ4.0市場規模は2024年から2030年にかけて18.96%のCAGRを記録し、2030年までに357億9,000万米ドルに達する見込みです。

ファーマ4.0市場は、個別化医療に対する需要の高まり、効率改善とコスト削減の必要性、サプライチェーンの最適化、患者中心のアプローチへの注目の高まりなど、いくつかの重要な要因によって牽引されています。慢性疾患や希少疾患の有病率の増加により、個別化医療への需要が高まっています。アディティブ・マニュファクチャリング（3Dプリンティング）やモジュール式生産設備などのファーマ4.0技術は、個々の患者のニーズに合わせた個別化医薬品や小ロットの生産を可能にし、この動向を後押ししています。

さらに、デジタル技術の採用が増加していることも、市場の成長を後押ししています。これらの技術は、医薬品開発、製造、流通、患者ケアを最適化、改善、変革します。ブロックチェーン技術は、透明性、トレーサビリティ、最適化を提供し、在庫切れを減らし、偽造を防止し、全体的な効率性と患者の安全性を高めることで、サプライチェーン管理を大幅に再構築しています。

さらに、製薬会社がファーマ4.0技術の採用に向けた投資を増やしていることも、市場成長の原動力となっています。例えば、アストラゼネカは、希少な神経変性疾患と神経筋疾患の標的同定に関して、最大8億4,000万米ドルの契約を締結しました。この契約の一環として、アストラゼネカのアレクシオン部門は、ヴァージ・ジェノミクスと協力して、これらの疾患の創薬標的を特定します。4年間のマルチターゲット契約期間中、両社は機械学習を利用して、細胞や動物モデルではなくヒト組織から得られたVerge社のゲノムデータセットを解析します。

ファーマ4.0市場レポートのハイライト

• 製品タイプ別では、効率向上、コンプライアンス向上、生産性向上など様々なメリットによりソフトウェアの採用が増加していることから、2023年にはソフトウェア分野が市場を独占しました。さらに、IoT対応ソフトウェアは、製造プロセスのリアルタイムモニタリングとトラッキングに役立ち、より良いプロセス制御につながり、ダウンタイムを削減します。
• 技術別では、AIの採用拡大と投資の増加により、AI＆ML分野が最大の市場シェアを占めています。例えば、ある調査によると、製薬企業の経営幹部の75％以上が、2025年までに創薬のスピードアップのためにAIを適用することを計画しています。
• 用途別では、創薬新興企業向けのAIへの投資が増加していることから、2023年には創薬・市場開拓が市場を独占しました。
• 医薬品・バイオテクノロジー分野は2023年に49.8%の最大市場シェアを占めました。製薬会社は、製造プロセスの効率性、生産性、品質を高めるためにファーマ4.0技術の採用を増やしており、それがこのセグメントの成長を牽引しています。
• 北米は2023年に41.12%の収益シェアを獲得し、世界市場を独占しました。この成長は、政府主導の増加、ヘルスケア産業における技術進歩、主要市場プレイヤーの強力なプレゼンスに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ファーマ4.0市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• ファーマ4.0市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響

第4章 ファーマ4.0市場：タイプ別推定・動向分析

• タイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• タイプ別：世界のファーマ4.0市場展望
• ソフトウェア
• サービス

第5章 ファーマ4.0市場：技術別推定・動向分析

• テクノロジー市場シェア、2023年と2030年
• セグメントダッシュボード
• 技術展：世界のファーマ4.0市場望別
• AIと機械学習
• ビッグデータ分析
• IoT
• ブロックチェーン技術
• その他（デジタルツイン、先進ロボティクス、AR＆VR）

第6章 ファーマ4.0市場：用途別推定・動向分析

• 用途別市場シェア、2023年および2030年
• セグメントダッシュボード
• 用途別：世界のファーマ4.0市場展望
• 医薬品の発見と開発
• 製造業
• サプライチェーンマネジメント
• その他（製品ライフサイクル管理、個別化医療、規制コンプライアンス）

第7章 ファーマ4.0市場：最終用途別推定・動向分析

• 最終用途別市場シェア、2023年および2030年
• セグメントダッシュボード
• 最終用途別：世界のファーマ4.0市場展望
• 製薬・バイオテクノロジー企業
• ヘルスケア提供者
• CROとCDMO

第8章 ファーマ4.0市場：地域別推定・動向分析、タイプ別、技術別、用途別、最終用途別

• 地域別市場シェア分析、2023年および2030年
• 地域別市場ダッシュボード
• 世界の地域市場スナップショット
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 主要企業の市場シェア分析、2023年
• 企業プロファイル
  • Microsoft Corporation
  • IBM
  • Amazon Web Service（AWS）
  • SAP
  • Oracle
  • GE Healthcare
  • Siemens Healthineers
  • Cisco
  • Cinntra
  • Dassault Systems
  • Nexocode

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Pharma 4.0 Market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 4 North America Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 6 North America Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 7 U.S. Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 10 U.S. Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 12 Canada Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 13 Canada Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 14 Canada Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 15 Mexico Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 16 Mexico Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 17 Mexico Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 18 Mexico Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe Pharma 4.0 Market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 21 Europe Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 22 Europe Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 23 Europe Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 24 Germany Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 25 Germany Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 26 Germany Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 27 Germany Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 28 UK Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 29 UK Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 30 UK Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 31 UK Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 32 France Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 33 France Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 34 France Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 35 France Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 36 Italy Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 37 Italy Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 38 Italy Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 39 Italy Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 40 Spain Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 41 Spain Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 42 Spain Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 43 Spain Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 44 Denmark Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 45 Denmark Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 46 Denmark Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 47 Denmark Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 48 Sweden Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 49 Sweden Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 50 Sweden Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 51 Sweden Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 52 Norway Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 53 Norway Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 54 Norway Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 55 Norway Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Pharma 4.0 Market, by region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 61 China Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 62 China Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 63 China Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 64 China Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 65 Japan Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 66 Japan Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 67 Japan Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 68 Japan Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 69 India Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 70 India Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 71 India Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 72 India Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 73 South Korea Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 74 South Korea Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 75 South Korea Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 76 South Korea Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 77 Australia Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 78 Australia Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 79 Australia Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 80 Australia Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 81 Thailand Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 82 Thailand Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 83 Thailand Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 84 Thailand Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 85 Latin America Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 86 Latin America Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 87 Latin America Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 88 Latin America Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 89 Brazil Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 90 Brazil Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 91 Brazil Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 92 Brazil Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 93 Argentina Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 94 Argentina Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 95 Argentina Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 96 Argentina Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 97 MEA Pharma 4.0 Market, by region, 2018 - 2030 (USD Million)
• Table 98 MEA Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 99 MEA Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 100 MEA Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 101 MEA Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 102 South Africa Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 103 South Africa Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 104 South Africa Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 105 South Africa Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 110 UAE Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 111 UAE Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 112 UAE Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 113 UAE Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)
• Table 114 Kuwait Pharma 4.0 Market, by type, 2018 - 2030 (USD Million)
• Table 115 Kuwait Pharma 4.0 Market, by technology, 2018 - 2030 (USD Million)
• Table 116 Kuwait Pharma 4.0 Market, by application, 2018 - 2030 (USD Million)
• Table 117 Kuwait Pharma 4.0 Market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Pharma 4.0 Market: market outlook
• Fig. 9 Cryostat competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Pharma 4.0 Market driver impact
• Fig. 15 Pharma 4.0 Market restraint impact
• Fig. 16 Pharma 4.0 Market strategic initiatives analysis
• Fig. 17 Pharma 4.0 Market: Type movement analysis
• Fig. 18 Pharma 4.0 Market: Type outlook and key takeaways
• Fig. 19 Software market estimates and forecast, 2018 - 2030
• Fig. 20 Services market estimates and forecast, 2018 - 2030
• Fig. 21 Pharma 4.0 Market: Technology movement analysis
• Fig. 22 Pharma 4.0 Market: Technology outlook and key takeaways
• Fig. 23 AI & ML market estimates and forecast, 2018 - 2030
• Fig. 24 Big data analytics market estimates and forecast, 2018 - 2030
• Fig. 25 IoT market estimates and forecast, 2018 - 2030
• Fig. 26 Block chain technology market estimates and forecast, 2018 - 2030
• Fig. 27 Others market estimates and forecast, 2018 - 2030
• Fig. 28 Pharma 4.0 Market: Application movement analysis
• Fig. 29 Pharma 4.0 Market: Application outlook and key takeaways
• Fig. 30 Drug Discovery & Development market estimates and forecast, 2018 - 2030
• Fig. 31 Manufacturing market estimates and forecast, 2018 - 2030
• Fig. 32 Supply Chain Management market estimates and forecast, 2018 - 2030
• Fig. 33 Others market estimates and forecast, 2018 - 2030
• Fig. 34 Pharma 4.0 Market: End Use movement analysis
• Fig. 35 Pharma 4.0 Market: End Use outlook and key takeaways
• Fig. 36 Pharma & Biotech companies market estimates and forecast, 2018 - 2030
• Fig. 37 Healthcare providers market estimates and forecast, 2018 - 2030
• Fig. 38 CRO & CDMO market estimates and forecast, 2018 - 2030
• Fig. 39 Global Pharma 4.0 Market: Regional movement analysis
• Fig. 40 Global Pharma 4.0 Market: Regional outlook and key takeaways
• Fig. 41 Global Pharma 4.0 Market share and leading players
• Fig. 42 North America market share and leading players
• Fig. 43 Europe market share and leading players
• Fig. 44 Asia Pacific market share and leading players
• Fig. 45 Latin America market share and leading players
• Fig. 46 Middle East & Africa market share and leading players
• Fig. 47 North America: SWOT
• Fig. 48 Europe SWOT
• Fig. 49 Asia Pacific SWOT
• Fig. 50 Latin America SWOT
• Fig. 51 MEA SWOT
• Fig. 52 North America, by country
• Fig. 53 North America market estimates and forecasts, 2018 - 2030
• Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 55 Canada market estimates and forecasts, 2018 - 2030
• Fig. 56 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 57 Europe market estimates and forecasts, 2018 - 2030
• Fig. 58 UK market estimates and forecasts, 2018 - 2030
• Fig. 59 Germany market estimates and forecasts, 2018 - 2030
• Fig. 60 France market estimates and forecasts, 2018 - 2030
• Fig. 61 Italy market estimates and forecasts, 2018 - 2030
• Fig. 62 Spain market estimates and forecasts, 2018 - 2030
• Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 64 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 65 Norway market estimates and forecasts, 2018 - 2030
• Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 67 China market estimates and forecasts, 2018 - 2030
• Fig. 68 Japan market estimates and forecasts, 2018 - 2030
• Fig. 69 India market estimates and forecasts, 2018 - 2030
• Fig. 70 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 71 Australia market estimates and forecasts, 2018 - 2030
• Fig. 72 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 73 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 74 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 75 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 76 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 77 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 78 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 79 UAE market estimates and forecasts, 2018 - 2030
• Fig. 80 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 81 Market share of key market players- Pharma 4.0 Market

Pharma 4.0 Market Growth & Trends:

The global pharma 4.0 market size is expected to reach USD 35.79 billion by 2030, registering a CAGR of 18.96% from 2024 to 2030, according to a new report by Grand View Research, Inc. The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.

In addition, increasing adoption of digital technologies is driving the market growth. These technologies optimize, improve, and revolutionize drug development, manufacturing, distribution, and patient care. Blockchain technology has significantly reshaped supply chain management by offering transparency, traceability, and optimization, reducing stockouts, preventing counterfeiting, and enhancing overall efficiency and patient safety.

Furthermore, the market growth is being driven by increasing investments from pharmaceutical companies in adopting Pharma 4.0 technologies. For example, AstraZeneca signed a deal worth up to USD 840 million for the target identification of rare neurodegenerative and neuromuscular diseases. As part of this deal, AstraZeneca's Alexion division will collaborate with Verge Genomics to identify drug targets for these conditions. Over the course of the four-year, multi-target agreement, the companies will utilize machine learning to analyze Verge's genomic datasets, which are derived from human tissue rather than cell or animal models.

Pharma 4. 0 Market Report Highlights:

• On the basis of type, the software segment dominated the market in 2023, owing to the increasing adoption of software due to various benefits such as efficiency enhancement, improved compliance and productivity. In addition, the IoT enabled software help in real time monitoring and tracking of manufacturing process, leading to better process control and reduces the downtime
• On the basis of technology, the AI & ML segment held the largest market share owing to growing adoption of AI and increasing investments. For instance, as per a survey, over 75% of pharma executives plan to apply AI to speed drug discovery by 2025
• On the basis of application, the drug discovery & development dominated the market in 2023 due to increased investment in AI for drug discovery startups
• Pharma & biotech segment held the largest market share of 49.8% in 2023. Pharmaceutical companies are increasingly adopting Pharma 4.0 technologies to enhance efficiency, productivity, and quality in their manufacturing processes thereby driving the segment growth
• North America dominated the global market with a revenue share of 41.12% in 2023. The growth is attributed to the increasing government initiative, technological advancement in the healthcare industry, and a strong presence of key market players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Technology
  • 1.1.3. Application
  • 1.1.4. End Use
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharma 4.0 Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharma 4.0 Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. COVID-19 Impact

Chapter 4. Pharma 4.0 Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Pharma 4.0 Market by Type Outlook
• 4.4. Software
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.5. Services
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Pharma 4.0 Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Pharma 4.0 Market by Technology Outlook
• 5.4. AI & ML
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.5. Big Data Analytics
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.6. IoT
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.7. Block chain Technology
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.8. Others (Digital twin, Advanced robotics, AR &VR)
  • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Pharma 4.0 Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Pharma 4.0 Market by Application Outlook
• 6.4. Drug Discovery & Development
  • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 6.5. Manufacturing
  • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 6.6. Supply Chain Management
  • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 6.7. Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)
  • 6.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 7. Pharma 4.0 Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Pharma 4.0 Market by End Use Outlook
• 7.4. Pharma & Biotech companies
  • 7.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 7.5. Healthcare Providers
  • 7.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 7.6. CRO & CDMO
  • 7.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 8. Pharma 4.0 Market: Regional Estimates & Trend Analysis, By type, By technology, By Application, By End Use

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Key company market share analysis, 2023
• 9.4. Company Profiles
  • 9.4.1. Microsoft Corporation
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. IBM
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Amazon Web Service (AWS)
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. SAP
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Oracle
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. GE Healthcare
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Siemens Healthineers
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Cisco
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Cinntra
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Dassault Systems
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Nexocode
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives